Awardee OrganizationCENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA
Description
Abstract Text
Summary – KZN-CTU
The KwaZulu-Natal Clinical Trials Unit (KZN-CTU), strategically located in the epicentre of one of the
world’s most severe HIV and tuberculosis epidemics, seamlessly combines the Clinical Research Sites (CRSs)
of existing, high-performing CTUs at CAPRISA and the South African Medical Research Council (SAMRC). In
the current funding cycle, the combined CTUs enrolled 4,713 participants in 28 protocols, with an overall
retention rate of 93%. Further, several KZN-CTU scientists participated at the highest levels in the Clinical Trial
Networks (CTNs), making influential new scientific contributions, including as network Protocol Chairs, that
have impacted global policy/practice, including tenofovir-containing PrEP for HIV prevention, co-treatment
strategies to reduce HIV-tuberculosis deaths and nevirapine prophylaxis to reduce breastfeeding transmission.
This renewal application’s goal is to make even greater contributions to the scientific priorities of all 4
CTNs through novel research concepts, innovative prevention technologies (eg. CAPRISA 256 antibody) and
high-quality clinical trials in high priority populations by experienced research teams at well-equipped CRSs.
The KZN-CTU, led by Quarraisha Abdool Karim of CAPRISA, comprises 4 components: i) Leadership and
governance, ii) Coordination and monitoring, and iii) 8 CRSs, supported by iv) 8 research support cores.
The Leadership and governance component will ensure effective CTU decision-making and governance,
active engagement with each CTN and oversee the efficient functioning of the CTU. The Coordination and
monitoring component is responsible for coordination of clinical trial implementation at high quality. The 8
CRSs, with HIV incidence rates ranging from 4.6 to 8.2 per 100 person-years in recent trials, are in the highest
burden districts of South Africa with diverse populations suited to HIV prevention, vaccine and treatment trials
as well as trials in children, adolescents and pregnant women. The Support Cores work with all the CRSs
providing assistance in the conduct of clinical trials, with administration and financial resource management,
communication, evaluation, training and quality assurance, community engagement, pharmacy, laboratory,
data management and IT, and regulatory compliance. The CTU’s organizational structures (Leadership Group,
Executive Committee and Community Advisory Boards) and communication tools (regular meetings, video
conferences, monthly newsletters and an informative website) enable effective communication, coordination
and governance in the unit. The KZN-CTU has groundswell support from KwaZulu-Natal community groups
and high-level political backing of the National and Provincial Departments of Health.
Overall, the KZN-CTU has well-characterized high-risk populations, well-established clinical facilities,
accredited laboratories, pharmacies, and data management systems, strong community linkages, and
extensive experience in conducting clinical trials, together with a track record of scientific innovation available
to support all 4 CTNs in developing new approaches to HIV and tuberculosis prevention and treatment.
Public Health Relevance Statement
In the global HIV epidemic, Africa accounts for about 70% of the 38 million people living with HIV (PLHIV) and
the 1.7 million new infections. In South Africa, which has a fifth of all the PLHIV in the world, the province of
KwaZulu-Natal bears a disproportionate burden, with 2 million PLHIV. In this province, community-based adult
HIV prevalence exceeds 30% and incidence rates exceed 4 per 100 person-years. KwaZulu-Natal also has a
substantial tuberculosis burden, with 50,822 new cases of tuberculosis (incidence of 494 per 100,000) in 2018,
of which about 60% are co-infected with HIV. The KwaZulu-Natal Clinical Trials Unit’s overall goal is to
contribute to the scientific priorities of the four Clinical Trial Networks through novel research concepts,
innovative prevention technologies and high-quality clinical trials in target populations by highly experienced
research teams at well-equipped Clinical Research Sites.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
639174239
UEI
X6AFCYA4LKV7
Project Start Date
01-March-2007
Project End Date
30-November-2027
Budget Start Date
01-December-2024
Budget End Date
30-November-2025
Project Funding Information for 2025
Total Funding
$1,043,933
Direct Costs
$993,165
Indirect Costs
$50,768
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$1,043,933
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UM1AI069469-19
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UM1AI069469-19
Patents
No Patents information available for 5UM1AI069469-19
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UM1AI069469-19
Clinical Studies
No Clinical Studies information available for 5UM1AI069469-19
News and More
Related News Releases
No news release information available for 5UM1AI069469-19
History
No Historical information available for 5UM1AI069469-19
Similar Projects
No Similar Projects information available for 5UM1AI069469-19